According to GlobalData, the US vaccination rate for seasonal influenza during the 2023-2024 season was estimated to be 47%, ...
According to GlobalData, the US vaccination rate for seasonal influenza during the 2023-2024 season was estimated to be 47%, ...
The US FDA has granted approval for AstraZeneca's FluMist, a needle-free nasal spray influenza vaccine for ...
The Food and Drug Administration announced Friday it had broadened the approval of the FluMist nasal spray to become the ...
AstraZeneca has just scored big on the quest to make routine vaccinations less of a hassle. | The FDA signed off on ...
FluMist is the first vaccine to prevent influenza that does not need to be administered by a healthcare provider, the ...
The FDA has approved at-home self- or caregiver-administration of FluMist (influenza vaccine live, intranasal).
The US Food and Drug Administration (FDA) has approved AstraZeneca's FluMist, a needle-free nasal spray influenza vaccine for self-administration. The approval makes FluMist the only 'flu vaccine ...
AstraZeneca PLC (LSE/STO/Nasdaq: LON:AZN) has received approval from the US Food and Drug Administration (FDA) for its FluMist influenza vaccine to be self-administered, marking a significant ...